Belite Bio, Inc (BLTE)

Belite Bio Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-77.61	-36.14	-31.63	-12.65	-9.67
Depreciation & Amortization	0.18	0.17	0.14	0.2	0.03
Loss (Gain) From Sale of Assets	-	-	-	-	-0.01
Loss (Gain) From Sale of Investments	-	-0.05	-	-	-
Stock-Based Compensation	38.92	8.99	3.82	1.48	1.53
Other Operating Activities	-1.03	-3.33	0.26	-	-
Change in Accounts Receivable	-	0.02	-0.02	-0.03	-
Change in Accounts Payable	-0.01	0.01	-	-0.04	0.05
Change in Other Net Operating Assets	2.56	1.1	-2.41	-0.42	0.6
Operating Cash Flow	-36.99	-29.23	-29.84	-11.46	-7.47
Capital Expenditures	-0.18	-0.12	-0.06	-0.39	-0.07
Sale of Property, Plant & Equipment	-	-	-	-	0.02
Sale (Purchase) of Intangibles	-	-0.04	-	-	-
Investment in Securities	-304.93	-110.42	-	-	-
Investing Cash Flow	-305.11	-110.57	-0.06	-0.39	-0.06
Issuance of Common Stock	139.81	58.2	77.19	37.99	0.23
Other Financing Activities	523.42	25.39	-1.23	-1.03	-0.82
Financing Cash Flow	663.23	83.6	75.96	36.96	-0.58
Foreign Exchange Rate Adjustments	0.12	-0.27	0.01	-0.37	-0.16
Net Cash Flow	321.26	-56.48	46.07	24.75	-8.27
Free Cash Flow	-37.17	-29.35	-29.9	-11.85	-7.55
Free Cash Flow Per Share	-1.11	-0.96	-1.12	-0.59	-0.79
Cash Interest Paid	0	-	-	0.02	-
Cash Income Tax Paid	-	0.01	0.01	-	-
Levered Free Cash Flow	-9.77	-13.7	-15.56	-7.1	-4.01
Unlevered Free Cash Flow	-9.76	-13.69	-15.54	-7.09	-4.01
Change in Working Capital	2.55	1.13	-2.43	-0.49	0.64

Updated Mar 2, 2026. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q